“Revolutionizing Heart Care & Empowering Patients:” Sirolimus-Driven Balloon Innovation Emerges as a More Effective Alternative to Stents in Larger Arteries https://www.taxtmi.com/news?id=62122 Cordis acquired MedAlliance for USD 1.135 billion, taking control of the patented SELUTION sirolimus drug eluting balloon and its proprietary Sustained Limus Release (SLR) technology; SELUTION is commercially available in over 65 countries and is under investigation in the United States, with clinical trial data presented claiming parity with drug eluting stents and implications for regulatory review and market authorizations. en-us Wed, 19 Nov 2025 18:16:03 +0530 Wed, 19 Nov 2025 18:16:03 +0530 TaxTMI RSS Generator “Revolutionizing Heart Care & Empowering Patients:” Sirolimus-Driven Balloon Innovation Emerges as a More Effective Alternative to Stents in Larger Arteries https://www.taxtmi.com/news?id=62122 Cordis acquired MedAlliance for USD 1.135 billion, taking control of the patented SELUTION sirolimus drug eluting balloon and its proprietary Sustained Limus Release (SLR) technology; SELUTION is commercially available in over 65 countries and is under investigation in the United States, with clinical trial data presented claiming parity with drug eluting stents and implications for regulatory review and market authorizations. News - Wed, 19 Nov 2025 18:16:03 +0530 https://www.taxtmi.com/news?id=62122